Application of a novel NF-kB inhibitor as anticancer drug for urothelial cancer
| Project/Area Number |
19591871
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
HORIGUCHI Yutaka Tokyo Medical University, 医学部, 講師 (60229234)
|
|---|
| Project Period (FY) |
2007 – 2008
|
| Project Status |
Completed (Fiscal Year 2008)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2007: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 尿路上皮癌 / 分子標的治療 / NF-kB / 転写因子 / アポトーシス / CPT-11 / NF-κB |
|---|
| Research Abstract |
本研究において、これまでほとんど研究がなされていなかった進行性尿路上皮癌における転写因子NF-kBの役割と、新規NF-kB活性阻害剤DHMEQの作用、その阻害機構が解明された。これをもとに抗癌剤CPT-11によるNF-kB活性化をDHMEQにより抑制することにより、膀胱癌に対する抗腫瘍効果の増強が示された。DHMEQとCPT-11の併用は新規膀胱癌治療として期待できると考えられた。
|
Report
(3 results)
Research Products
(6 results)
-
[Journal Article] Establishment and characterization of a new squamous cell carcinoma cell line, TMUU-08, derived from human bladder cancer2009
Author(s)
Ozu, C., Takeuchi, H., Matsushita, K., Horiguchi, Y., et al.(合計8名中4番目)
-
Journal Title
Human Cell 22
Pages: 25-29
Related Report
Peer Reviewed
-
-
[Journal Article] Establish ment of orthotopic mouse superficial bladder tumor model for studies on intrav esical treatments2008
Author(s)
Horiguchi, Y., Kikuchi, E.,Ozu, C., Nishiyama, T., Oyama, M., Horinaga, M., Yoshioka, K., Tachibana, M
-
Journal Title
Human Cell 21
Pages: 57-63
Related Report
Peer Reviewed
-
-
-
